Sleep Loss and Mechanisms of Impaired Glucose Metabolism
Status:
Completed
Trial end date:
2008-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the effects of sleep and eszopiclone, a drug that helps
people sleep, on how the body processes glucose (sugar). Eszopiclone is approved by the U.S.
Food and Drug Administration (FDA) for sale for the treatment of insomnia. It is marketed in
the United States as LUNESTA.
Main Hypothesis: Primary insomnia is associated with impairments of glucose metabolism that
can be reversed by two months of eszopiclone for the primary insomnia
Phase:
N/A
Details
Lead Sponsor:
Brigham and Women's Hospital
Collaborators:
Mclean Hospital National Center for Research Resources (NCRR) Sunovion